Last reviewed · How we verify
Pegasys&Entecavir
This combination uses peginterferon alfa-2a to stimulate immune response against hepatitis B virus and entecavir to directly inhibit viral reverse transcriptase, providing dual antiviral activity.
This combination uses peginterferon alfa-2a to stimulate immune response against hepatitis B virus and entecavir to directly inhibit viral reverse transcriptase, providing dual antiviral activity. Used for Chronic hepatitis B infection, Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
At a glance
| Generic name | Pegasys&Entecavir |
|---|---|
| Also known as | No other names |
| Sponsor | National Taiwan University Hospital |
| Drug class | Combination antiviral therapy (interferon + nucleoside reverse transcriptase inhibitor) |
| Target | Hepatitis B virus polymerase; interferon-alpha receptor signaling |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Pegasys (peginterferon alfa-2a) is an interferon that enhances innate and adaptive immune responses to clear HBV-infected cells. Entecavir is a nucleoside reverse transcriptase inhibitor that blocks HBV polymerase and prevents viral replication. Together, they target both viral replication and host immune activation for hepatitis B treatment.
Approved indications
- Chronic hepatitis B infection
- Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Neutropenia
- Thrombocytopenia
- Depression/mood changes
- Nausea
- Alopecia
Key clinical trials
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (PHASE2)
- Impact of Fatty Liver on Hepatitis B Therapy
- A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection (PHASE2)
- HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV
- To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs. (NA)
- A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |